The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against C. jejuni in a subject comprising one or more MeOPN-6-Gal monosaccharides, one or more MeOPN-4-Gal monosaccharides, and/or one or more MeOPN-2-Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs, and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic constructs, to the subject. Methods of treating, preventing, or ameliorating a C. jejuni bacterial infection in a subject comprising administering to the subject one or more doses of immunoglobulins directed to one or more of the MeOPN moieties are also contemplated.

The present invention relates to the fields of sexually transmitted disease and immunology. More specifically, but not exclusively, the invention provides a composition and methods to prepare and administer a vaccine for Neisseria gonorrhoede and/or other gram-negative bacteria such as by using psoralen-inactivated bacteria.

The invention relates to an adenovirus comprising a nucleic acid sequence encoding a Helicobacter pylori neutrophil-activating protein (NAP) and/or a nucleic acid sequence encoding an immunologically equivalent fragment of NAP and a nucleic acid sequence encoding an immunomodulator capable of inducing an immune response in a subject. The adenovirus has enhanced clinical effects in terms of delaying tumor growth and prolonging survival.

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the shedding of Lawsonia intracellularis bacteria associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and non-replicating immunogen of Mycoplasma hyopneumoniae and an adjuvant containing a nano-emulsion of mineral oil in water, for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with Mycoplasma hyopneumoniae by administration of the vaccine into the dermis of the animal.

The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which comprise a therapeutically effective amount of a Immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS), in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. IN other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.